TrialSignal
Clinical trial intelligence report
Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05054218-Jul 28, 2026
NCT ID
NCT05054218
Status
COMPLETED
Phase
registry-stage
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Executive brief
Investment-Ready Snapshot
Immunogenicity of a Third Dose of mRNA-1273 Vaccine (Moderna) Among Cancer Patients is a registry-stage clinical asset sponsored by H. Lee Moffitt Cancer Center and Research Institute in Covid19, SARS-CoV2 Infection. SEO and diligence focus: mRNA-1273, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05054218
Indication
Covid19
Modality
RNA therapy
Target
mRNA-1273
Intervention
mRNA-1273
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.